---
title: "Bacterial Infections"
order: 1
category: "Infectious Diseases"
---

# Bacterial Infections

## Overview

Bacterial infections remain a leading cause of morbidity and mortality worldwide despite advances in antimicrobial therapy. This chapter covers major bacterial infections including sepsis, infective endocarditis, meningitis, tuberculosis, and Lyme disease. Understanding the pathophysiology, clinical presentation, diagnostic approach, and evidence-based treatment of these conditions is essential for all clinicians.

## Sepsis and Septic Shock

### Overview

Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. It represents a continuum from infection to sepsis to septic shock, with increasing severity and mortality. Early recognition and prompt treatment are critical to improve outcomes.

### Epidemiology

- 49 million cases of sepsis globally per year
- 11 million sepsis-related deaths annually (20% of all deaths worldwide)
- United States: 1.7 million sepsis cases, 270,000 deaths annually
- Leading cause of death in hospitalized patients
- Hospital costs: >$24 billion annually in US
- Mortality: 10-20% (sepsis), 40% (septic shock)

### Definitions (Sepsis-3, 2016)

**Infection**: Documented or suspected, confirmed by positive culture or clinical syndrome

**Sepsis**: Life-threatening organ dysfunction caused by dysregulated host response to infection
- Defined by increase in SOFA (Sequential Organ Failure Assessment) score ≥2 points
- Baseline SOFA assumed to be 0 in patients without known organ dysfunction

**Septic shock**: Subset of sepsis with profound circulatory, cellular, and metabolic abnormalities
- Criteria: Sepsis + vasopressor requirement to maintain MAP ≥65 mmHg + lactate >2 mmol/L despite adequate fluid resuscitation
- Hospital mortality >40%

**Quick SOFA (qSOFA)**: Bedside screening tool (≥2 of 3 criteria suggests sepsis)
- Respiratory rate ≥22/min
- Altered mental status (GCS <15)
- Systolic blood pressure ≤100 mmHg

### Pathophysiology

**Normal response to infection**:
- Localized inflammatory response
- Pathogen recognition (PAMPs, DAMPs)
- Innate immune activation (neutrophils, macrophages, complement)
- Adaptive immune response
- Pathogen clearance, tissue repair

**Dysregulated response in sepsis**:
- Excessive inflammation (cytokine storm: TNF-α, IL-1, IL-6, IL-8)
- Endothelial dysfunction and increased vascular permeability
- Coagulation activation (microvascular thrombosis)
- Complement activation
- Mitochondrial dysfunction
- Immunosuppression (late phase)

**Organ dysfunction**:
- **Cardiovascular**: Vasodilation, myocardial depression, hypovolemia → shock
- **Respiratory**: ARDS, acute lung injury
- **Renal**: Acute kidney injury (hypoperfusion, inflammation)
- **Hepatic**: Cholestasis, elevated transaminases
- **Hematologic**: Thrombocytopenia, DIC
- **CNS**: Encephalopathy, delirium
- **Metabolic**: Lactic acidosis, hyperglycemia

### Clinical Presentation

**Symptoms**:
- Fever (>38.3°C) or hypothermia (<36°C)
- Chills, rigors
- Altered mental status (confusion, agitation, somnolence)
- Dyspnea
- Nausea, vomiting, diarrhea, abdominal pain

**Signs**:
- Tachycardia (>90 bpm)
- Tachypnea (>20/min or PaCO2 <32 mmHg)
- Hypotension (SBP <90 mmHg or MAP <65 mmHg)
- Delayed capillary refill, mottled skin
- Oliguria (<0.5 mL/kg/hr)

**Common sources**:
- Lung (pneumonia): 50%
- Abdomen (peritonitis, cholangitis, appendicitis): 25%
- Urinary tract (pyelonephritis, urosepsis): 15%
- Skin/soft tissue (cellulitis, necrotizing fasciitis): 5%
- Bloodstream (catheter-related): 5%
- Unknown: 10-20%

### Diagnosis

**Clinical criteria**: Sepsis-3 definitions (above)

**Laboratory**:
- **Blood cultures**: 2-3 sets from different sites before antibiotics (positive in 30-50%)
- **Lactate**: Elevated (>2 mmol/L) indicates tissue hypoperfusion, poor prognosis
- **Complete blood count**: Leukocytosis (>12,000) or leukopenia (<4,000), left shift, thrombocytopenia
- **Metabolic panel**: Creatinine (AKI), glucose, liver function tests
- **Coagulation**: PT/INR, PTT (DIC if prolonged), fibrinogen, D-dimer
- **Arterial blood gas**: Metabolic acidosis (pH <7.35, low HCO3)
- **Procalcitonin**: Elevated in bacterial infection (>0.5 ng/mL), guides antibiotic duration

**Imaging**:
- Chest X-ray (pneumonia)
- CT abdomen/pelvis (intra-abdominal source)
- Ultrasound (cholecystitis, abscess)
- Echocardiography (endocarditis if bacteremia)

**Source cultures**:
- Urine culture
- Sputum culture
- Wound culture
- CSF (if meningitis suspected)

### Treatment

**Hour-1 Bundle** (Surviving Sepsis Campaign 2021):

1. **Measure lactate level**: Remeasure if initial >2 mmol/L
2. **Obtain blood cultures before antibiotics**
3. **Administer broad-spectrum antibiotics**
4. **Begin rapid IV fluid resuscitation** (30 mL/kg crystalloid for hypotension or lactate ≥4 mmol/L)
5. **Vasopressors if hypotensive during or after fluid resuscitation** (maintain MAP ≥65 mmHg)

**Antimicrobial therapy**:

*Empiric antibiotics* (within 1 hour):
- **Community-acquired sepsis**: Piperacillin-tazobactam or cefepime or meropenem
  - Add vancomycin if MRSA risk (IV drug use, prior MRSA, skin infection)
  - Add azithromycin if atypical pneumonia suspected
- **Healthcare-associated sepsis**: Antipseudomonal beta-lactam (piperacillin-tazobactam, cefepime, meropenem) + vancomycin or linezolid
  - Add antifungal (echinocandin) if high risk (TPN, broad-spectrum antibiotics, immunosuppressed)
- **Neutropenic fever**: Antipseudomonal beta-lactam ± aminoglycoside ± vancomycin
- **Intra-abdominal source**: Add metronidazole or ensure anaerobic coverage

*De-escalation*:
- Narrow spectrum based on culture results and susceptibilities
- Stop vancomycin if no MRSA
- Discontinue antibiotics if no infection identified and clinical improvement

*Duration*:
- 7-10 days for most infections (source-dependent)
- Shorter duration if source controlled
- Procalcitonin-guided therapy can reduce antibiotic exposure

**Fluid resuscitation**:
- Initial: 30 mL/kg crystalloid (balanced crystalloids like lactated Ringer's preferred over normal saline)
- Assess fluid responsiveness: Passive leg raise, pulse pressure variation (if mechanically ventilated)
- Avoid fluid overload (pulmonary edema, abdominal compartment syndrome)
- Target: MAP ≥65 mmHg, urine output ≥0.5 mL/kg/hr, lactate clearance

**Vasopressor therapy** (if hypotensive despite fluids):
- **Norepinephrine**: First-line vasopressor
  - Start 0.05-0.1 mcg/kg/min, titrate to MAP ≥65 mmHg
- **Vasopressin**: Add-on to norepinephrine (0.03-0.04 units/min, fixed dose)
- **Epinephrine**: Second-line if inadequate response
- **Dopamine**: Alternative to norepinephrine (if low risk of arrhythmias)
- **Phenylephrine**: Pure vasoconstrictor, if tachyarrhythmias contraindicate other agents

**Corticosteroids**:
- **Hydrocortisone 200 mg/day** (continuous infusion or divided doses) if:
  - Refractory shock despite adequate fluids and vasopressors
  - Not routinely recommended for all septic shock
- Duration: Until shock resolves, then taper

**Source control**:
- Critical for survival
- Drain abscesses (percutaneous or surgical)
- Debride necrotic tissue (necrotizing fasciitis)
- Remove infected foreign bodies (catheters, prostheses)
- Relieve obstruction (biliary, urinary)
- Ideally within 6-12 hours of diagnosis

**Supportive care**:
- **Mechanical ventilation**: Lung-protective ventilation (tidal volume 6 mL/kg ideal body weight, plateau pressure <30 cmH2O) if ARDS
- **Renal replacement therapy**: If severe AKI, volume overload, electrolyte abnormalities
- **Glucose control**: Target <180 mg/dL
- **DVT prophylaxis**: Pharmacologic (unless contraindicated)
- **Stress ulcer prophylaxis**: PPI or H2 blocker if risk factors
- **Nutrition**: Enteral nutrition preferred over parenteral

### Complications

- Acute respiratory distress syndrome (ARDS)
- Acute kidney injury (AKI)
- Disseminated intravascular coagulation (DIC)
- Multiorgan dysfunction syndrome (MODS)
- Death

### Prognosis

- Sepsis mortality: 10-20%
- Septic shock mortality: 40-50%
- Survivors: Long-term sequelae (cognitive impairment, physical disability, PTSD, increased risk of future infections)

## Infective Endocarditis

### Overview

Infective endocarditis (IE) is a microbial infection of the endocardial surface of the heart, most commonly affecting heart valves. It is associated with significant morbidity and mortality despite advances in diagnosis and treatment.

### Epidemiology

- Incidence: 3-10 per 100,000 person-years
- Mean age: 50-60 years (increasing with aging population)
- Male predominance (2:1)
- Hospital mortality: 15-20%
- 1-year mortality: 40%
- Leading cause of death from bacterial infection in developed countries

### Risk Factors

**Cardiac conditions**:
- Prosthetic heart valves (highest risk)
- Previous infective endocarditis
- Congenital heart disease (cyanotic, repaired with prosthetic material)
- Rheumatic heart disease (developing countries)
- Degenerative valve disease (calcific aortic stenosis, mitral valve prolapse)

**Non-cardiac risk factors**:
- Intravenous drug use (IVDU): Increasing cause, often affects tricuspid valve
- Intravascular catheters (hemodialysis, central lines)
- Implantable cardiac devices (pacemakers, ICDs)
- Poor dentition, dental procedures
- Immunosuppression (diabetes, HIV, malignancy)

### Microbiology

**Native valve endocarditis**:
- Streptococcus viridans (40-50%): Oral flora, subacute presentation
- Staphylococcus aureus (30-40%): Acute presentation, high mortality
- Enterococcus species (10%): GI/GU source, resistant to many antibiotics
- Coagulase-negative staphylococci (5%)
- HACEK organisms (2-3%): Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, Kingella (slow-growing, good prognosis)

**Prosthetic valve endocarditis**:
- Early (<1 year): Coagulase-negative staphylococci, S. aureus (nosocomial)
- Late (>1 year): Similar to native valve (S. viridans, S. aureus, enterococci)

**IVDU-associated**:
- S. aureus (>50%, often MRSA)
- Streptococci, enterococci
- Gram-negative bacilli (Pseudomonas)
- Fungi (Candida)

**Culture-negative endocarditis** (5-10%):
- Prior antibiotics (most common)
- Fastidious organisms: Coxiella burnetii (Q fever), Bartonella, Brucella, Tropheryma whipplei
- Fungi

### Pathophysiology

**Sequence of events**:
1. Endothelial injury (turbulent blood flow, IV catheters, cardiac devices)
2. Platelet-fibrin deposition (nonbacterial thrombotic endocarditis)
3. Transient bacteremia (dental procedures, IV drug use, GI/GU procedures, skin infections)
4. Bacterial adherence to sterile vegetation
5. Vegetation formation (bacteria embedded in fibrin-platelet matrix)
6. Local extension (valve destruction, abscess, fistula)
7. Systemic complications (embolization, immune complex deposition)

### Clinical Presentation

**Symptoms**:
- Fever (85-90%): Most common symptom
- Chills, night sweats
- Malaise, fatigue, weight loss
- Dyspnea (heart failure)
- Arthralgias, myalgias
- Stroke/TIA (embolic)

**Signs**:
- **Cardiac**:
  - New or changing murmur (80-85%): Regurgitant murmur most common
  - Heart failure (30-40%): Acute valve regurgitation
- **Peripheral manifestations**:
  - Petechiae (20-40%): Conjunctival, oral mucosa, extremities
  - Splinter hemorrhages (15%): Linear subungual lesions
  - Osler nodes (10%): Painful nodules on finger/toe pads (immune complex)
  - Janeway lesions (5%): Painless hemorrhagic macules on palms/soles (septic emboli)
  - Roth spots (5%): Retinal hemorrhages with white center
- **Splenomegaly** (30%)
- **Neurologic**: Stroke, intracranial hemorrhage (mycotic aneurysm), meningitis, brain abscess

**Presentation patterns**:
- **Acute** (S. aureus): Rapid onset, high fever, toxic appearance, heart failure, emboli
- **Subacute** (viridans strep): Insidious onset, low-grade fever, nonspecific symptoms, weeks to months

### Diagnosis

**Modified Duke Criteria**:

*Definite endocarditis*: 2 major, 1 major + 3 minor, or 5 minor criteria

*Possible endocarditis*: 1 major + 1 minor, or 3 minor criteria

**Major criteria**:
1. **Positive blood cultures**:
   - Typical IE organisms in 2 separate blood cultures (S. viridans, S. aureus, enterococci, HACEK)
   - Persistently positive blood cultures (drawn >12 hours apart) or ≥3 positive cultures
   - Single positive for Coxiella burnetii or IgG titer >1:800
2. **Evidence of endocardial involvement** (echocardiography):
   - Vegetation
   - Abscess, pseudoaneurysm, intracardiac fistula
   - New valvular regurgitation
   - Prosthetic valve dehiscence

**Minor criteria**:
- Predisposing condition (valvular disease, IVDU)
- Fever ≥38.0°C
- Vascular phenomena: Arterial emboli, septic pulmonary infarcts, mycotic aneurysm, intracranial hemorrhage, Janeway lesions
- Immunologic phenomena: Glomerulonephritis, Osler nodes, Roth spots, rheumatoid factor
- Microbiologic evidence: Positive blood culture not meeting major criterion or serologic evidence of active infection

**Diagnostic workup**:

*Blood cultures*:
- 3 sets from different sites, ideally before antibiotics
- If prior antibiotics, delay cultures 48-72 hours if stable
- Hold for 5-7 days (HACEK organisms)
- Notify lab if HACEK, Brucella, fungi suspected (special media, prolonged incubation)

*Echocardiography*:
- **Transthoracic echocardiography (TTE)**: First-line, sensitivity 60-70% for vegetations
- **Transesophageal echocardiography (TEE)**: Superior sensitivity (>90%), especially for:
  - Prosthetic valves
  - Suspected complications (abscess, perforation, fistula)
  - Negative TTE with high clinical suspicion
  - Small vegetations (<10 mm)

*Other tests*:
- Complete blood count (anemia, leukocytosis)
- Inflammatory markers (ESR, CRP)
- Urinalysis (hematuria, proteinuria from glomerulonephritis)
- Rheumatoid factor (often positive)
- Complement levels (low in immune complex disease)
- Cardiac biomarkers (heart failure)
- ECG (conduction abnormalities suggest abscess)
- CT/MRI brain (if neurologic symptoms)

### Treatment

**Antimicrobial therapy** (prolonged IV antibiotics):

*Native valve endocarditis*:

**Streptococcus viridans or bovis** (penicillin-susceptible, MIC ≤0.12 mcg/mL):
- Penicillin G 12-18 million units/day IV continuous or divided every 4 hours × 4 weeks OR
- Ceftriaxone 2 g IV daily × 4 weeks OR
- Penicillin G or ceftriaxone (above) + gentamicin 3 mg/kg IV daily × 2 weeks (shorter course)

**Staphylococcus aureus** (methicillin-susceptible):
- Nafcillin or oxacillin 12 g/day IV divided every 4 hours × 6 weeks ± gentamicin 3 mg/kg IV daily × 3-5 days (optional, may improve rate of clearance)

**Staphylococcus aureus** (methicillin-resistant, MRSA):
- Vancomycin 15-20 mg/kg IV every 8-12 hours (target trough 15-20 mcg/mL) × 6 weeks OR
- Daptomycin 8-10 mg/kg IV daily × 6 weeks (preferred by some)

**Enterococcus** (ampicillin-susceptible):
- Ampicillin 12 g/day IV divided every 4 hours + gentamicin 3 mg/kg IV daily × 4-6 weeks OR
- Penicillin G 18-30 million units/day + gentamicin (as above)

**Enterococcus** (vancomycin-susceptible, ampicillin-resistant):
- Vancomycin 15-20 mg/kg IV every 8-12 hours + gentamicin 3 mg/kg IV daily × 6 weeks

**Enterococcus** (vancomycin-resistant, VRE):
- Daptomycin 10-12 mg/kg IV daily + ampicillin (if susceptible) or linezolid 600 mg IV/PO every 12 hours

*Prosthetic valve endocarditis*:
- Longer duration (≥6 weeks)
- Often combination therapy with rifampin
- Surgical consultation recommended

*Empiric therapy* (before cultures):
- Native valve: Vancomycin + ceftriaxone ± gentamicin
- Prosthetic valve: Vancomycin + gentamicin + rifampin

**Surgical indications** (30-50% of cases):

*Heart failure*:
- Acute severe valve regurgitation with pulmonary edema or cardiogenic shock
- Most common indication (40%)

*Uncontrolled infection*:
- Persistent bacteremia >5-7 days despite appropriate antibiotics
- Abscess, pseudoaneurysm, fistula, enlarging vegetation
- Fungal or resistant organisms (VRE, multidrug-resistant Gram-negatives)

*Prevention of embolism*:
- Large vegetation (>10 mm) with embolic event
- Very large vegetation (>15 mm) on anterior mitral leaflet

*Prosthetic valve dysfunction*:
- Dehiscence, obstruction

**Timing of surgery**:
- Emergent: Cardiogenic shock, refractory pulmonary edema
- Urgent (within days): Heart failure, uncontrolled infection
- Elective: Large vegetations, relapsing infection
- Neurologic complications: Delay if possible (risk of hemorrhagic transformation with anticoagulation during bypass)

### Complications

- Heart failure (30-40%): Most common cause of death
- Embolic events (20-50%): Stroke, splenic/renal infarcts, septic pulmonary emboli (right-sided)
- Perivalvular abscess (10-20%)
- Mycotic aneurysm (2-10%): Intracranial most concerning
- Acute kidney injury (30%): Sepsis, emboli, immune complex glomerulonephritis, antibiotic toxicity
- Conduction abnormalities (5-15%): Suggests abscess extension into septum
- Metastatic infections: Vertebral osteomyelitis, septic arthritis, splenic abscess

### Prognosis

- In-hospital mortality: 15-20%
- 1-year mortality: 40%
- Worse prognosis: S. aureus, prosthetic valve, heart failure, CNS involvement, abscess, older age, comorbidities

### Prevention (Antibiotic Prophylaxis)

**Indications** (AHA 2007 guidelines, very restrictive):
- High-risk cardiac conditions:
  - Prosthetic valves
  - Previous infective endocarditis
  - Congenital heart disease (unrepaired cyanotic, repaired with prosthetic material within 6 months, or residual defects)
  - Cardiac transplant with valvulopathy

**Procedures**:
- Dental procedures involving manipulation of gingival tissue or periapical region
- Respiratory tract procedures involving incision of mucosa (NOT bronchoscopy)

**Regimen**:
- Amoxicillin 2 g PO 30-60 minutes before procedure
- If allergic: Clindamycin 600 mg or azithromycin 500 mg or cephalexin 2 g

**NOT recommended**:
- GI or GU procedures
- Other valvular heart disease (mitral valve prolapse, aortic stenosis)

## Bacterial Meningitis

### Overview

Bacterial meningitis is a life-threatening infection of the meninges surrounding the brain and spinal cord. Despite effective antibiotics, it remains associated with significant morbidity (neurologic sequelae) and mortality. Prompt recognition and empiric treatment are critical.

### Epidemiology

- Incidence: 1-2 per 100,000 per year (developed countries)
- 1.2 million cases worldwide, 135,000 deaths annually
- Mortality: 10-30% (despite treatment)
- Neurologic sequelae: 20-50% of survivors (hearing loss, cognitive impairment, seizures)
- Most common in infants, elderly, immunocompromised

### Microbiology (Age- and Risk Factor-Dependent)

**Neonates (<1 month)**:
- Group B Streptococcus (Streptococcus agalactiae)
- Escherichia coli and other Gram-negative bacilli
- Listeria monocytogenes

**Infants/children (1 month - 18 years)**:
- Streptococcus pneumoniae (most common)
- Neisseria meningitidis
- Haemophilus influenzae type b (rare since vaccine)

**Adults (18-50 years)**:
- S. pneumoniae (50%)
- N. meningitidis (30%)
- H. influenzae (rare)

**Adults (>50 years) or immunocompromised**:
- S. pneumoniae (most common)
- L. monocytogenes
- Gram-negative bacilli (E. coli, Klebsiella, Pseudomonas)

**Post-neurosurgery or head trauma**:
- Staphylococcus aureus (MSSA, MRSA)
- Coagulase-negative staphylococci
- Gram-negative bacilli (Pseudomonas, Acinetobacter)

### Pathophysiology

1. **Nasopharyngeal colonization** (S. pneumoniae, N. meningitidis)
2. **Mucosal invasion** → bacteremia
3. **Hematogenous seeding** of meninges (across blood-CSF barrier)
4. **Bacterial replication** in CSF (minimal host defenses)
5. **Inflammatory response**: Cytokines (TNF-α, IL-1, IL-6), neutrophil influx
6. **Increased intracranial pressure**: Cerebral edema (vasogenic, cytotoxic, interstitial)
7. **Complications**: Decreased cerebral blood flow, ischemia, infarction, herniation

### Clinical Presentation

**Classic triad** (only 44% have all three):
- Fever
- Headache
- Nuchal rigidity (stiff neck)

**Additional symptoms/signs**:
- Altered mental status (confusion, lethargy, coma): 80%
- Photophobia
- Nausea, vomiting
- Seizures (30%)
- Focal neurologic deficits (10-30%)

**Physical examination**:
- **Nuchal rigidity**: Inability to flex neck, resistance to passive flexion
- **Kernig sign**: With hip flexed 90°, pain/resistance to knee extension
- **Brudzinski sign**: Hip/knee flexion when neck is flexed
- **Petechial or purpuric rash** (40% with N. meningitidis): Suggests meningococcemia
- **Papilledema** (rare, late): Increased intracranial pressure
- **Cranial nerve palsies** (VI most common)

**Presentation patterns**:
- **Acute** (<24 hours): N. meningitidis, S. pneumoniae
- **Subacute** (days): L. monocytogenes, tuberculosis, fungal

### Diagnosis

**Lumbar puncture (LP)** - CRITICAL:

*Timing*:
- Perform IMMEDIATELY if no contraindications
- Do NOT delay for imaging if no focal deficits or papilledema (low risk of herniation)

*Contraindications to immediate LP*:
- Focal neurologic deficit
- New-onset seizure
- Papilledema
- Immunocompromised (risk of mass lesion)
- Glasgow Coma Scale (GCS) <12
→ Obtain CT head first, then LP if safe (but start empiric antibiotics first)

*CSF analysis*:

**Bacterial meningitis findings**:
- **Opening pressure**: Elevated (>20-25 cm H2O)
- **Appearance**: Cloudy, turbid, purulent
- **White blood cells**: Elevated (100-10,000/μL, usually >1,000), neutrophil predominance (>80%)
- **Protein**: Elevated (>100-500 mg/dL, often >200)
- **Glucose**: Decreased (<40 mg/dL or CSF:serum ratio <0.4)
- **Gram stain**: Positive in 60-90% (depends on organism, prior antibiotics)
- **Culture**: Positive in 70-80% (lower if prior antibiotics)
- **Bacterial antigens**: PCR or latex agglutination (S. pneumoniae, N. meningitidis)

**Comparison with viral meningitis**:
- Viral: Lymphocytic predominance, normal glucose, mildly elevated protein (<100)

**Other tests**:
- Blood cultures (before antibiotics): Positive in 50-80%
- Procalcitonin (elevated in bacterial vs viral)
- Complete blood count (leukocytosis)
- Serum glucose (for CSF:serum ratio)

**Imaging**:
- CT head if contraindications to LP (see above)
- MRI more sensitive for complications (abscess, empyema, ventriculitis, infarction)

### Treatment

**KEY PRINCIPLE: Do NOT delay antibiotics for LP or imaging**
- If LP delayed (e.g., awaiting CT), give empiric antibiotics immediately after blood cultures

**Empiric antimicrobial therapy** (adjust for organism once identified):

*Age- and risk-based empiric regimens*:

**Adults <50 years, immunocompetent**:
- Vancomycin 15-20 mg/kg IV every 8-12 hours (target trough 15-20) PLUS
- Ceftriaxone 2 g IV every 12 hours OR cefotaxime 2 g IV every 4-6 hours
- Covers S. pneumoniae (including resistant), N. meningitidis

**Adults ≥50 years or immunocompromised** (add Listeria coverage):
- Vancomycin + ceftriaxone + ampicillin 2 g IV every 4 hours

**Post-neurosurgery, head trauma, CSF shunt**:
- Vancomycin + cefepime 2 g IV every 8 hours OR meropenem 2 g IV every 8 hours
- Covers S. aureus (MRSA), Pseudomonas, resistant Gram-negatives

*Organism-specific therapy* (after identification):

**Streptococcus pneumoniae**:
- **Penicillin-susceptible** (MIC <0.06): Penicillin G 24 million units/day IV continuous or divided every 4 hours × 10-14 days
- **Penicillin-nonsusceptible** or unknown: Vancomycin + ceftriaxone × 10-14 days

**Neisseria meningitidis**:
- Penicillin G 24 million units/day IV × 7 days OR
- Ceftriaxone 2 g IV every 12 hours × 7 days

**Listeria monocytogenes**:
- Ampicillin 2 g IV every 4 hours + gentamicin 5-7 mg/kg IV daily × 21 days (minimum)

**Haemophilus influenzae**:
- Ceftriaxone 2 g IV every 12 hours × 7 days

**Gram-negative bacilli** (Pseudomonas, Enterobacteriaceae):
- Cefepime 2 g IV every 8 hours OR meropenem 2 g IV every 8 hours × 21 days

**Staphylococcus aureus**:
- **MSSA**: Nafcillin 2 g IV every 4 hours × 14 days
- **MRSA**: Vancomycin × 14 days

**Adjunctive corticosteroids**:
- **Dexamethasone 10 mg IV every 6 hours × 4 days**
- Give 10-20 minutes before or with first antibiotic dose
- Indications:
  - **Strongly recommended**: S. pneumoniae (reduces mortality, neurologic sequelae)
  - Consider: H. influenzae
  - Not recommended: N. meningitidis (no benefit), low-income countries (may harm)

**Supportive care**:
- ICU monitoring (if altered mental status, hemodynamic instability)
- Fluid resuscitation (if septic shock)
- Seizure management (antiepileptics)
- Monitor for increased intracranial pressure (head elevation, avoid hypotonic fluids)
- Consider mannitol or hypertonic saline if cerebral edema
- Mechanical ventilation if respiratory failure, GCS <8

### Complications

- Hearing loss (30%): Cochlear inflammation (most common sequela)
- Cognitive impairment (memory, learning disabilities)
- Seizures (recurrent)
- Focal neurologic deficits (cranial nerve palsies, hemiparesis)
- Hydrocephalus (communicating or obstructive)
- Subdural empyema or effusion
- Brain abscess
- Cerebral venous thrombosis
- Cerebral infarction
- Death (10-30%)

### Prognosis

- Mortality: 10-30% (S. pneumoniae 20-30%, N. meningitidis 5-15%, L. monocytogenes 20-30%)
- Poor prognostic factors: Older age, altered mental status on presentation, seizures, low CSF glucose, delay in treatment, S. pneumoniae

### Prevention

**Vaccination**:
- Pneumococcal: PCV20 or PCV15+PPSV23 (adults ≥65, risk factors)
- Meningococcal: MenACWY, MenB (adolescents, college students, high-risk)
- Haemophilus influenzae type b (Hib): Routine childhood immunization

**Chemoprophylaxis for close contacts**:
- **N. meningitidis** (household, daycare, direct exposure to secretions):
  - Rifampin 600 mg PO twice daily × 2 days OR
  - Ciprofloxacin 500 mg PO single dose OR
  - Ceftriaxone 250 mg IM single dose
- **H. influenzae type b**: Rifampin (household contacts with unvaccinated children)

## Tuberculosis

### Overview

Tuberculosis (TB) is a chronic infection caused by Mycobacterium tuberculosis complex, primarily affecting the lungs but capable of disseminating to any organ. Despite being curable, TB remains a major global health problem, particularly in resource-limited settings and among immunocompromised populations.

### Epidemiology

- 10.6 million new TB cases worldwide (2021)
- 1.6 million TB deaths annually (second leading infectious cause of death after COVID-19)
- One-quarter of world's population has latent TB infection (LTBI)
- 5-10% lifetime risk of progression from LTBI to active TB (higher if immunocompromised)
- United States: 7,860 cases (2021), declining incidence
- High burden countries: India, China, Indonesia, Philippines, Pakistan, Nigeria, Bangladesh, South Africa

### Risk Factors

**Exposure risk**:
- Close contact with active TB case (household, healthcare)
- Birth or residence in high-prevalence country
- Homelessness, incarceration, congregate living
- Healthcare workers

**Progression from latent to active TB**:
- HIV infection (highest risk, 5-10% per year)
- Recent infection (<2 years)
- Immunosuppression: TNF-α inhibitors, corticosteroids, chemotherapy, transplant
- Chronic kidney disease, dialysis
- Diabetes mellitus
- Malnutrition, low body weight
- Smoking, alcohol use disorder
- Silicosis
- Prior gastrectomy, jejunoileal bypass

### Pathophysiology

**Primary infection** (initial exposure):
1. Inhalation of M. tuberculosis (aerosolized droplet nuclei)
2. Alveolar macrophage phagocytosis
3. Bacterial replication within macrophages (prevent phagolysosomal fusion)
4. Hematogenous and lymphatic spread
5. Cell-mediated immunity develops (2-10 weeks)
6. Granuloma formation (Langerhans giant cells, epithelioid histiocytes, caseous necrosis)
7. Containment (latent TB) in 90-95%
8. Primary progressive TB in 5-10% (immunocompromised, young children)

**Latent TB infection (LTBI)**:
- Viable but dormant bacteria within granulomas
- No symptoms, not infectious
- Positive tuberculin skin test (TST) or interferon-gamma release assay (IGRA)
- Normal chest X-ray or calcified granulomas
- 5-10% lifetime risk of reactivation

**Active TB (reactivation)**:
- Granuloma breakdown, bacterial replication
- Pulmonary (85%) or extrapulmonary (15%)
- Symptomatic, infectious (if pulmonary with cavitation)

### Clinical Presentation

**Pulmonary TB** (most common):

*Symptoms*:
- **Chronic cough** (>2-3 weeks): Most common symptom
- Hemoptysis (blood-streaked sputum or frank bleeding)
- Chest pain (pleuritic)
- Dyspnea (advanced disease)
- **Constitutional symptoms**: Fever (low-grade, afternoon), night sweats, weight loss, malaise, fatigue

*Physical examination*:
- Often normal
- Rales, bronchial breath sounds (upper lobes)
- Signs of consolidation
- Cachexia (advanced)

**Extrapulmonary TB** (15-20%, higher in HIV):
- **Lymphatic** (most common): Cervical lymphadenopathy (scrofula), painless, matted, may suppurate
- **Pleural**: Pleuritic chest pain, pleural effusion (exudative, lymphocyte-predominant)
- **Skeletal**: Vertebral (Pott disease, back pain, gibbus deformity), septic arthritis
- **Genitourinary**: Sterile pyuria, hematuria, flank pain
- **CNS**: Meningitis (basilar, cranial nerve palsies), tuberculoma (mass lesion)
- **Miliary (disseminated)**: Hematogenous spread, multiple organs, fever, hepatosplenomegaly, pancytopenia, ARDS
- **Pericardial**: Pericarditis, effusion, tamponade, constrictive pericarditis
- **Abdominal**: Peritonitis (ascites), bowel involvement

### Diagnosis

**Screening for latent TB**:

*Tuberculin skin test (TST, Mantoux)*:
- Intradermal injection of purified protein derivative (PPD)
- Read 48-72 hours (measure induration, not erythema)
- **Positive criteria** (depends on risk):
  - ≥5 mm: HIV, recent TB contact, CXR with fibrotic changes, immunosuppressed (TNF-α inhibitors, steroids ≥15 mg/day prednisone × 1 month)
  - ≥10 mm: Recent immigrant (<5 years) from high-prevalence country, IVDU, healthcare worker, homeless, incarcerated, diabetes, chronic kidney disease, silicosis, children <4 years
  - ≥15 mm: No risk factors
- False positives: BCG vaccine (wanes over time), nontuberculous mycobacteria
- False negatives: Anergy (immunosuppressed, disseminated TB)

*Interferon-gamma release assay (IGRA)*:
- Blood test: QuantiFERON-TB Gold, T-SPOT.TB
- Detects IFN-γ release by T cells in response to M. tuberculosis antigens
- Not affected by BCG vaccine
- Preferred in BCG-vaccinated individuals
- False negatives if severely immunocompromised

**Diagnosis of active TB**:

*Chest imaging*:
- **Chest X-ray**:
  - Primary TB: Hilar/paratracheal lymphadenopathy, lower/middle lobe infiltrate, pleural effusion
  - Reactivation TB: Upper lobe infiltrates (apical/posterior segments), cavitation (highly infectious)
  - Miliary TB: Diffuse micronodular pattern (1-3 mm)
- **CT chest**: More sensitive, cavitation, tree-in-bud (endobronchial spread)

*Microbiologic diagnosis*:

**Sputum examination** (3 samples, early morning):
- **Acid-fast bacilli (AFB) smear**: Sensitivity 50-80% (if cavitary), rapid (same day)
  - Auramine-rhodamine (fluorescent) or Ziehl-Neelsen (carbolfuchsin)
  - Positive: Indicates high bacterial burden, infectious
- **Mycobacterial culture**: Gold standard, takes 2-8 weeks
  - Liquid media (MGIT) faster than solid (Lowenstein-Jensen)
  - Speciation, drug susceptibility testing
- **Nucleic acid amplification test (NAAT)**: Rapid (hours), moderate sensitivity
  - Xpert MTB/RIF: Detects M. tuberculosis and rifampin resistance simultaneously
  - Recommended by WHO as initial diagnostic test

**Extrapulmonary TB**:
- Biopsy of affected site (lymph node, pleura, bone, etc.)
- Histopathology: Caseating granulomas with Langerhans giant cells
- AFB stain and culture of tissue/fluid
- Pleural fluid: Exudative, lymphocyte-predominant, low glucose, elevated adenosine deaminase (ADA >40 U/L suggestive)

*Other tests*:
- HIV test (all TB patients)
- Liver function tests (baseline before treatment)
- Hepatitis B and C serology

### Treatment

**Latent TB infection (LTBI)**:

*Indications*: Positive TST/IGRA + no active disease (normal CXR, no symptoms)

*Regimens*:
- **Isoniazid + rifapentine (3HP)**: 300 mg isoniazid + 900 mg rifapentine weekly × 12 weeks (preferred, directly observed)
- **Rifampin (4R)**: 10 mg/kg (max 600 mg) daily × 4 months (alternative, better tolerated than isoniazid)
- **Isoniazid (9H)**: 5 mg/kg (max 300 mg) daily × 9 months (traditional, higher discontinuation due to hepatotoxicity)

*Monitoring*: Clinical assessment for hepatotoxicity (nausea, vomiting, jaundice, abdominal pain)

**Active TB disease**:

*Directly observed therapy (DOT)* recommended

**Intensive phase** (2 months): Kill rapidly dividing bacteria, prevent resistance

**RIPE regimen** (first-line):
- **R**ifampin 10 mg/kg (max 600 mg) daily
- **I**soniazid 5 mg/kg (max 300 mg) daily + pyridoxine (vitamin B6) 25-50 mg daily
- **P**yrazinamide 20-25 mg/kg (max 2 g) daily
- **E**thambutol 15-20 mg/kg (max 1.6 g) daily

**Continuation phase** (4 months): Rifampin + isoniazid daily

*Total duration*:
- Pulmonary TB (drug-susceptible): 6 months
- Extrapulmonary TB: 6-12 months (CNS, bone: 9-12 months)

*Drug-resistant TB*:
- **Isoniazid-resistant**: Rifampin + ethambutol + pyrazinamide + fluoroquinolone × 6-9 months
- **Rifampin-resistant**: 18-24 months, multiple second-line drugs
- **Multidrug-resistant (MDR-TB)**: Resistant to isoniazid + rifampin, requires ≥4 drugs (fluoroquinolones, injectables, bedaquiline, linezolid) × 18-24 months
- **Extensively drug-resistant (XDR-TB)**: MDR + resistant to fluoroquinolone + injectable, very difficult to treat

**Monitoring during treatment**:
- Clinical response: Symptoms improve within 2-4 weeks
- Sputum cultures: Repeat monthly until negative (expect conversion by 2 months)
- Liver function tests: Baseline, then monitor if symptoms or risk factors (isoniazid, rifampin, pyrazinamide hepatotoxic)
- Vision testing (ethambutol): Baseline and monthly (optic neuritis)
- Adherence assessment

**Drug interactions**:
- Rifampin: Potent CYP450 inducer, reduces levels of many drugs (antiretrovirals, oral contraceptives, warfarin, anticonvulsants)

### Complications

- Drug-resistant TB (treatment failure)
- Hemoptysis (Rasmussen aneurysm, aspergilloma in cavity)
- Respiratory failure, ARDS
- Empyema
- Pericardial tamponade, constrictive pericarditis
- Adrenal insufficiency (bilateral adrenal TB)
- Death (untreated TB mortality ~50%)

### Prognosis

- Drug-susceptible pulmonary TB: Cure rate >95% with adherent treatment
- MDR-TB: Cure rate 50-60%
- XDR-TB: Cure rate <30%

### Infection Control

- **Airborne precautions**: Negative pressure room, N95 respirators for healthcare workers
- Patients remain in isolation until:
  - 3 consecutive negative AFB smears (at least 8 hours apart) OR
  - Clinical improvement + ≥2 weeks appropriate therapy
- Contact investigation: Screen close contacts with TST/IGRA

## Lyme Disease

### Overview

Lyme disease is the most common vector-borne disease in the United States, caused by the spirochete Borrelia burgdorferi (and B. mayonii in upper Midwest) and transmitted by Ixodes ticks (deer tick, black-legged tick). It is characterized by early localized infection (erythema migrans rash), with potential for dissemination to joints, heart, and nervous system if untreated.

### Epidemiology

- 30,000-40,000 confirmed cases annually in US (likely significant underreporting)
- Endemic areas: Northeast, Mid-Atlantic, Upper Midwest, northern California
- Seasonal: Spring through fall (May-October), peak June-July
- Vector: Ixodes scapularis (East/Midwest), I. pacificus (West)
- Nymphal ticks (small, ~poppy seed size) responsible for most transmission
- Attachment >36-48 hours required for transmission

### Pathophysiology

1. Tick bite, attachment
2. B. burgdorferi in tick midgut activated by blood meal
3. Migration to salivary glands
4. Inoculation into skin (requires >36 hours attachment)
5. Local replication → erythema migrans
6. Hematogenous and lymphatic dissemination (days to weeks)
7. Immune evasion (antigenic variation)
8. Organ involvement: Skin, joints, heart, nervous system

### Clinical Presentation

**Stage 1: Early localized (3-30 days after bite)**:

- **Erythema migrans (EM)**: 70-80% of cases
  - Expanding erythematous patch/plaque at bite site
  - Typically >5 cm (average 15 cm)
  - Central clearing ("bull's-eye") in 20-30% (not required for diagnosis)
  - Warm, not painful or pruritic
  - Resolves spontaneously in weeks without treatment
  - Multiple lesions (20%): Dissemination
- Viral-like illness: Fatigue, malaise, arthralgias, myalgias, headache, fever

**Stage 2: Early disseminated (days to weeks later)**:

- **Multiple erythema migrans** (20%): Secondary lesions smaller than primary
- **Neurologic (10-15%)**:
  - **Cranial neuropathy**: Facial nerve palsy (uni- or bilateral, distinguish from stroke/Bell's palsy)
  - **Lymphocytic meningitis**: Headache, neck stiffness, fever
  - **Radiculoneuritis** (Bannwarth syndrome): Severe pain, sensory/motor deficits
- **Cardiac (1-2%)**:
  - **Atrioventricular (AV) block**: First-degree, second-degree (Mobitz I or II), third-degree (complete heart block)
  - Myocarditis, pericarditis (rare)
  - Usually resolves spontaneously or with antibiotics
- **Musculoskeletal**: Migratory arthralgias, myalgias

**Stage 3: Late disseminated (months to years later, if untreated)**:

- **Lyme arthritis (60% if untreated)**:
  - Large joint monoarthritis or oligoarthritis (knee most common, 90%)
  - Intermittent swelling, pain
  - Large effusions
  - Responds to antibiotics in most cases
- **Chronic neurologic**:
  - Subtle encephalopathy: Memory, concentration impairment
  - Polyneuropathy: Sensory symptoms, paresthesias
  - Encephalomyelitis (rare)
- **Acrodermatitis chronica atrophicans** (Europe): Chronic skin lesion, bluish-red discoloration, atrophy

### Diagnosis

**Early localized Lyme** (erythema migrans):
- **Clinical diagnosis**: EM rash + endemic area + potential tick exposure
- **Do NOT test**: Serology often negative early, treat empirically
- Serology may be sent but should not delay treatment

**Disseminated or late Lyme**:
- **Two-tier serology** (CDC-recommended):
  1. **ELISA** (enzyme immunoassay): Screen for antibodies to B. burgdorferi
     - If negative and symptoms <30 days: Repeat in 2-4 weeks (convalescent serology)
     - If negative and symptoms >30 days: Lyme unlikely
  2. **Western blot** (if ELISA positive or equivocal): Confirmatory
     - IgM: Positive if ≥2 of 3 bands (23, 39, 41 kDa) - only interpret if symptoms <30 days
     - IgG: Positive if ≥5 of 10 bands
- **IgM appears 2-4 weeks**, peaks 6-8 weeks, declines
- **IgG appears 6-8 weeks**, remains positive for years (even after treatment)
- **False positives**: Syphilis, EBV, autoimmune diseases

**Lyme arthritis**:
- Synovial fluid: Inflammatory (WBC 10,000-25,000, PMN predominance)
- PCR of synovial fluid: More sensitive than culture

**Neuroborreliosis**:
- CSF: Lymphocytic pleocytosis, elevated protein, normal glucose
- Intrathecal antibody production: CSF antibody index

**Lyme carditis**:
- ECG: Prolonged PR interval, AV block
- Echocardiography if myocarditis suspected

### Treatment

**Early localized or early disseminated** (without neurologic or cardiac involvement):

- **Doxycycline**: 100 mg PO twice daily × 10-14 days (preferred if not contraindicated)
- **Amoxicillin**: 500 mg PO three times daily × 14 days (pregnancy, age <8 years)
- **Cefuroxime**: 500 mg PO twice daily × 14 days (alternative)

**Neurologic Lyme** (meningitis, radiculoneuritis):

- **Ceftriaxone**: 2 g IV daily × 14-28 days (preferred for CNS involvement)
- **Doxycycline** 100 mg PO twice daily × 14-28 days: Alternative for isolated facial palsy without meningitis

**Lyme carditis**:

- **Mild (first-degree AV block, PR <300 ms)**: Doxycycline PO × 14-21 days
- **Moderate-severe (higher degree AV block, PR >300 ms, symptomatic)**: Ceftriaxone IV × 14-21 days
- **Temporary pacemaker**: If complete heart block or symptomatic bradycardia (usually resolves in 1-2 weeks)
- **Hospital admission**: Recommended for AV block monitoring

**Lyme arthritis**:

- **Doxycycline** or amoxicillin PO × 28 days (first-line)
- **Ceftriaxone** IV × 28 days: If persistent after oral antibiotics or neurologic involvement
- NSAIDs for symptom relief
- Arthrocentesis (therapeutic drainage if large effusion)
- Synovectomy (if persistent inflammation despite antibiotics)

**Post-treatment Lyme disease syndrome (PTLDS)**:
- 10-20% report persistent symptoms (fatigue, pain, cognitive impairment) after treatment
- NOT active infection (negative tests, antibodies persist)
- Prolonged antibiotics NOT beneficial (multiple RCTs)
- Supportive care, symptomatic management

**Prophylaxis** (after tick bite):
- **Doxycycline 200 mg single dose** (within 72 hours of tick removal) if:
  - Tick identified as I. scapularis
  - Attached ≥36 hours (engorged)
  - Local Lyme prevalence >20%
  - Not contraindicated (age ≥8 years, not pregnant)
- Otherwise: Watchful waiting, educate about EM rash

### Prevention

- Avoid tick habitat (wooded, brushy, grassy areas)
- Wear protective clothing (long sleeves, pants tucked into socks)
- Use insect repellent (DEET, picaridin, permethrin on clothing)
- Tick checks after outdoor activities (remove within 24-36 hours prevents transmission)
- Proper tick removal: Grasp with fine-tipped tweezers close to skin, pull upward with steady pressure
- Landscape modification (remove leaf litter, create barriers)
- No effective human vaccine currently available (LYMErix withdrawn 2002)

### Complications

- Chronic arthritis (10% antibiotic-refractory)
- Persistent neurologic deficits (rare)
- Carditis complications (rare, usually resolves)
- Post-treatment Lyme disease syndrome (10-20%)

### Prognosis

- Excellent with early treatment (erythema migrans: >95% cure)
- Delayed treatment: Higher risk of dissemination, prolonged symptoms
- Late Lyme: Usually responsive to antibiotics, but recovery may be slower

## Key Points

- Sepsis is defined as SOFA score ≥2 with infection; septic shock requires vasopressors and lactate >2 mmol/L despite fluids, with mortality >40%
- The Hour-1 Bundle for sepsis includes measuring lactate, obtaining blood cultures, administering broad-spectrum antibiotics, initiating fluid resuscitation (30 mL/kg), and starting vasopressors if needed
- Infective endocarditis diagnosis uses Modified Duke Criteria requiring positive blood cultures and echocardiographic evidence (vegetation, abscess, new regurgitation)
- Bacterial meningitis requires immediate empiric antibiotics (do NOT delay for LP or imaging); dexamethasone reduces mortality in pneumococcal meningitis
- CSF in bacterial meningitis shows neutrophilic pleocytosis (>80% PMNs), elevated protein (>100 mg/dL), and low glucose (<40 or CSF:serum <0.4)
- Tuberculosis treatment requires 6 months of RIPE therapy (rifampin, isoniazid, pyrazinamide, ethambutol) for drug-susceptible pulmonary TB
- Latent TB infection is treated with isoniazid-rifapentine weekly × 12 weeks or rifampin daily × 4 months to prevent progression to active disease
- Lyme disease presents with erythema migrans rash (70-80%), diagnosed clinically in endemic areas without serologic testing in early disease
- Early Lyme disease is treated with doxycycline 100 mg twice daily × 10-14 days; neuroborreliosis requires ceftriaxone IV × 14-28 days
- Post-exposure prophylaxis after tick bite (doxycycline 200 mg single dose) is indicated if Ixodes tick attached ≥36 hours in endemic area with >20% prevalence

## References

1. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-810.

2. Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med. 2021;49(11):e1063-e1143.

3. Baddour LM, Wilson WR, Bayer AS, et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation. 2015;132(15):1435-1486.

4. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice Guidelines for the Management of Bacterial Meningitis. Clin Infect Dis. 2004;39(9):1267-1284.

5. Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016;63(7):e147-e195.

6. World Health Organization. Global Tuberculosis Report 2022. Geneva: WHO; 2022.

7. Lantos PM, Rumbaugh J, Bockenstedt LK, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. Clin Infect Dis. 2021;72(1):e1-e48.

8. Steere AC, Strle F, Wormser GP, et al. Lyme Borreliosis. Nat Rev Dis Primers. 2016;2:16090.
